Evidence map›Paper›PMID 38057444›Full record

ArticleScientific reports2023

Safety evaluation of PEGylated MNPs and p-PEGylated MNPs in SD rats.

Hairuo Wen, Guitao Huo, Chao Qin, Hui Wu, Dan Wang, Mo Dan, Xingchao Geng, Shujie Liu

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Targeted therapeutic strategies for the kidney.Expert opinion on therapeutic targets · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hairuo WenNational Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China.
Guitao HuoNational Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China.
Chao QinNational Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China.
Hui WuNational Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China.
Dan WangNational Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China.
Mo DanNational Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China. dmo@cspc.cn.
Xingchao GengNational Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China. gengxch@nifdc.org.cn.
Shujie LiuNational Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China. shjliu1983@126.com.

Funding

Ministry of Science and Technology of the People's Republic of China 2018ZX09201017Ministry of Science and Technology of the People's Republic of China 81401517
6 · The paper itself

Abstract

Polyethylene glycol-coated magnetic nanoparticles (PEGylated MNPs) have demonstrated prominent advantages in cancer diagnosis and hyperthermia therapy. However, there is currently lack of standard mode and sufficient toxicity data for determining the delayed risk of PEGylated MNPs. Nevertheless, the toxicity potentials, especially those associated with the oxidative stress, were ubiquitously reported. In this study, PEGylated MNPs and p-PEGylated MNPs were administrated to SD (Sprague Dawley) rats by single intravenously injection, and various toxicity indicators were monitored till 56 days post-administration for a comprehensive toxicity evaluation. We revealed that both nanoparticles could be rapidly cleared from plasma and enter tissues, such as, liver, kidneys and spleen, and p-PEGylated MNP is less prone to be accumulated in the tissues, indicating a lower toxicity risk. PEGylated MNPs were more likely to up-regulate the expression levels of Th2 type cytokines and trigger inflammatory pathways, but no related pathological change was found. Both MNPs are not mutagenic, while recoverable mild DNA damage associated with the presence of nanoparticles might also be observed. This study demonstrated a research approach for the non-clinical safety evaluation of nanoparticles. It also provided comprehensive valuable safety data for PEGylated and p-PEGylated MNPs, for promoting the clinical application and bio-medical translation of such MNPs with PEG modifications in the cancer diagnosis and therapy.

Indexed as

Magnetite NanoparticlesNeoplasmsAnimalsLiverPolyethylene GlycolsRatsRats, Sprague-DawleyMagnetite NanoparticlesPolyethylene Glycols

Identifiers

PMID38057444
PMCPMC10700491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.